Evidence map›Paper›PMID 38958922›Full record

ArticleFrontiers of medicine2024

Acquired immune thrombotic thrombocytopenic purpura (TTP) associated with inactivated COVID-19 vaccine CoronaVac.

Zhangbiao Long, Suyu Jiang, Honglei Xin, Lu Zhang, Ruinan Lu, Fengqi Liu, Yong Xu, Linv Wang, Jun Wang, Xuezhong Zhang and 12 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Frontiers of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Zhangbiao Long *Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Suyu Jiang *Department of Hematology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210003, China.
Honglei Xin *Department of Hematology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210003, China.
Lu ZhangDepartment of Hematology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210003, China.
Ruinan LuDepartment of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.
Fengqi LiuDepartment of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.
Yong XuDepartment of Hematology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, China.
Linv WangDepartment of Hematology, The Affiliated Hospital of Nanjing University of Chinese Medicine, The First Clinical Medical College of Nanjing University of Chinese Medicine, Nanjing, 210009, China.
Jun WangDepartment of Hematology, Zhongda Hospital of Southeast University, Nanjing, 210044, China.
Xuezhong ZhangDepartment of Hematology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Hui LiaoDepartment of Hematology, The Air Force Hospital of Eastern Theater command, Nanjing, 210016, China.
Jinning ShiDepartment of Hematology, Jiangning Hospital Affiliated of Nanjing Medical University, Nanjing, 211199, China.
Xue YanDepartment of Hematology, Jiangning Hospital Affiliated of Nanjing Medical University, Nanjing, 211199, China.
Xiang ZhuDepartment of Hematology, Nanjing Hospital of Chinese Medicine, Nanjing, 210006, China.
Ruonan ShaoDepartment of Hematology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210003, China.
Zijian LiDepartment of Hematology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210003, China.
Yilin ZhuDepartment of Hematology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210003, China.
Han YanDepartment of Hematology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210003, China.
Jiao WuDepartment of Hematology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210003, China.
Chao FangDepartment of Pharmacology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, The Key Laboratory for Drug Target Researches and Pharmacodynamic Evaluation of Hubei Province, Wuhan, 430030, China. fangc@hust.edu.cn.
Xiaodong XiShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. xixiaodong@shsmu.edu.cn.
Xiaofeng ShiDepartment of Hematology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210003, China. shixiaofeng1977@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Corona virus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has affected the whole world. Acquired thrombotic thrombocytopenic purpura (TTP) has been reported after administration of mRNA- or adenoviral vector-based COVID-19 vaccines, including Ad26.COV2-S, BNT162b2, mRNA-1273, and ChAdOx1 nCov-19. However, whether inactivated vaccines, such as CoronaVac, could cause TTP and whether the symptoms in TTPs caused by inactivated vaccines are different from previously reported cases are unknown. In this study, two cases were reported. Both cases developed TTP after the second CoronaVac vaccination shot, but not the first. They demonstrated symptoms of fever, neurological abnormalities, renal dysfunction, thrombocytopenia, and hemolysis. Both patients achieved complete remission through several sessions of plasma exchanges and immune suppression. The incidence of TTP in Nanjing area was analyzed. The number of patients with TTP was 12 in 2019, 6 in 2020, 16 in 2021, and 19 in 2022. To the authors' knowledge, this report is the first report of TTP associated with inactivated COVID-19 vaccine (CoronaVac). The rarity and delayed onset may be due to the relatively milder immune response caused by the inactivated vaccines than mRNA-based ones. Timely plasma exchange is a vital treatment for CoronaVac-related TTP, similar to activated vaccine-related TTP.

Indexed as

COVID-19COVID-19 VaccinesPurpura, Thrombotic ThrombocytopenicVaccines, InactivatedAdultFemaleHumansMaleMiddle AgedPlasma ExchangeSARS-CoV-2COVID-19 Vaccinessinovac COVID-19 vaccineVaccines, Inactivatedacute respiratory syndrome coronavirus 2 (SARS-CoV-2)CoronaVaccorona virus disease 2019 (COVID-19)thrombotic thrombocytopenia purpura (TTP)vaccine

Identifiers

PMID38958922

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.